NASDAQ:LIXT Lixte Biotechnology - LIXT News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.79 +0.03 (+3.96%) (As of 01/31/2023 05:19 PM ET) Add Compare Share Share Today's Range$0.75▼$0.8050-Day Range$0.48▼$0.7752-Week Range$0.43▼$4.95Volume56,707 shsAverage Volume62,955 shsMarket Capitalization$13.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Media Mentions By Week LIXT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXT News Sentiment▼0.570.72▲Average Medical News Sentiment LIXT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXT Articles This Week▼40▲LIXT Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineGlobal Neurometabolic Disorders Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028marketwatch.com - January 26 at 1:26 AMLIXT Lixte Biotechnology Holdings, Inc.seekingalpha.com - January 25 at 3:25 PMLixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interestamericanbankingnews.com - January 24 at 6:50 AMNeurometabolic Disorders Market Latest Trends, Industry Size and Future Prospects 2028marketwatch.com - January 12 at 10:01 PMGaucher Disease Drugs Market Set to High Latest Developments, Growth Prospects 2023-2027 with Future Trends and Share Analysismarketwatch.com - January 4 at 9:09 AMNeurometabolic Disorders Market Analysis Report 2023 Along with Statistics Figures, Forecasts till 2028marketwatch.com - December 22 at 5:27 PMLIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conferencefinance.yahoo.com - November 30 at 12:13 PMNeurometabolic Disorders Market 2023 : Opportunities in Future, Business Growth Analysis by Top Countries Data and Industry Players by 2028marketwatch.com - November 25 at 11:39 PMPDS Biotech surges 22% as drug shows response in cervical cancer patients in phase 2 trialseekingalpha.com - November 16 at 9:36 PMLIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUPfinance.yahoo.com - October 13 at 1:26 PMLIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORSfinance.yahoo.com - June 21 at 11:30 AMLIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORSfinance.yahoo.com - June 15 at 9:28 AMLixte Biotechnology Holdings, Inc. (LIXT)finance.yahoo.com - June 14 at 9:00 PMWallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offeringfinance.yahoo.com - April 14 at 7:30 PMLIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Marketfinance.yahoo.com - April 14 at 7:30 PMWallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)finance.yahoo.com - April 13 at 12:53 PMWestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)finance.yahoo.com - April 13 at 12:53 PMHealthcare Breakthroughs: Atai, Nova Mentis, PolarityTE, and LIXTE; Biomed Leaders Report Latest Advances in Regenerative Tissue Technology, Psychedelics, and New Therapeutics for Autism, Mental Health and Cancersfinance.yahoo.com - April 13 at 12:53 PMWe're Keeping An Eye On Lixte Biotechnology Holdings' (NASDAQ:LIXT) Cash Burn Ratefinance.yahoo.com - April 13 at 12:53 PMLIXTE Biotechnology stock shoots on $5.8M direct offering priced ATMseekingalpha.com - April 12 at 4:36 PMLIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Marketfinance.yahoo.com - April 12 at 4:36 PMWhy Is Lixte Biotechnology (LIXT) Stock Up Today?investorplace.com - April 12 at 1:06 PMLixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancersmsn.com - April 12 at 11:36 AMThinking about buying stock in Lixte Biotechnology, Hoth Therapeutics, Ocugen, Bilibili, or Sunshine Biopharma?morningstar.com - April 12 at 11:36 AMLixte Biotech gains on anti-cancer activity of lead assetseekingalpha.com - April 12 at 11:36 AMLIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinationsfinance.yahoo.com - April 12 at 11:36 AMInactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapyfinance.yahoo.com - March 22 at 12:37 PMLIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conferencefinance.yahoo.com - March 16 at 10:32 AMLixte Biotechnology Holdings, Inc. Common Stock (LIXT)nasdaq.com - January 22 at 7:38 PMLixte Biotechnology Holdings Inc Shares Close the Week 21.6% Lower - Weekly Wrapnasdaq.com - January 18 at 9:00 PMLixte Biotech files first patent application for LB-100 combination therapy in cancerseekingalpha.com - January 12 at 11:25 AMLixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100finance.yahoo.com - January 12 at 11:25 AMLixte Biotechnology, Mainz Biomed lead healthcare gainers, Annexon, Hoth among losersseekingalpha.com - January 7 at 7:29 AMSee Why Lixte Biotech Shares Trading At Over 100%?msn.com - January 5 at 3:24 PMLixte Biotechnology Stock Surges on Positive Datamsn.com - January 5 at 3:24 PMLixte Biotechnology soars after pre-clinical research supporting its lead assetseekingalpha.com - January 5 at 10:24 AMLixte Biotechnology Shares Soar in Premarket on Positive Datamarketwatch.com - January 5 at 10:24 AMLixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumorsfinance.yahoo.com - January 5 at 10:24 AMLixte Biotech Holdings Shares Resume Trading; Up 22%benzinga.com - December 10 at 8:42 PMLIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORSfinance.yahoo.com - November 22 at 9:41 AMLixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28finance.yahoo.com - October 20 at 3:20 PMLixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatmentfinance.yahoo.com - October 13 at 9:47 AMBullish insiders at Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) loaded up on US$1.3m of stock earlier this yearnasdaq.com - September 26 at 1:01 PMWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growthfinance.yahoo.com - September 24 at 1:41 PMLixte Biotechnology Holdings Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Movernasdaq.com - September 22 at 9:49 AMLixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addictionfinance.yahoo.com - August 17 at 5:00 PMLixte's LB-100 Blocks Behavioral Sensitization In Animal Modelsfinance.yahoo.com - August 17 at 5:00 PMLixte Biotechnology Holdings Inc.barrons.com - August 8 at 11:44 PMLixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancermsn.com - August 3 at 4:10 PMLixte Biotechnology Shares Rise 31% on Positive Data for Lung Cancer Treatmentmarketwatch.com - August 3 at 4:10 PM Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:LIXT) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.